(Q86564392)
English
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage
scientific article published on 21 October 2013
Statements
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer (English)
Jyoti D Patel
Mark A Socinski
Edward B Garon
Craig H Reynolds
David R Spigel
Mark R Olsen
Robert C Hermann
Robert M Jotte
Thaddeus Beck
Donald A Richards
Susan C Guba
Jingyi Liu
Bente Frimodt-Moller
William J John
Coleman K Obasaju
Eduardo J Pennella
Philip Bonomi
Ramaswamy Govindan
21 October 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference